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Background: Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that acts through a family of five
G-protein-coupled receptors (S1PR1–5) and plays a key role in regulating the inflammatory response. Our previous
studies demonstrated that rat sensory neurons express the mRNAs for all five S1PRs and that S1P increases neuronal
excitability primarily, but not exclusively, through S1PR1. This raises the question as to which other S1PRs mediate
the enhanced excitability.
Methods: Isolated sensory neurons were treated with either short-interfering RNAs (siRNAs) or a variety of
pharmacological agents targeted to S1PR1/R2/R3 to determine the role(s) of these receptors in regulating neuronal
excitability. The excitability of isolated sensory neurons was assessed by using whole-cell patch-clamp recording
to measure the capacity of these cells to fire action potentials (APs).
Results: After siRNA treatment, exposure to S1P failed to augment the excitability. Pooled siRNA targeted to S1PR1
and R3 also blocked the enhanced excitability produced by S1P. Consistent with the siRNA results, pretreatment
with W146 and CAY10444, selective antagonists for S1PR1 and S1PR3, respectively, prevented the S1P-induced
increase in neuronal excitability. Similarly, S1P failed to augment excitability after pretreatment with either VPC
23019, which is a S1PR1 and R3 antagonist, or VPC 44116, the phosphonate analog of VPC 23019. Acute exposure
(10 to 15 min) to either of the well-established functional antagonists, FTY720 or CYM-5442, produced a significant
increase in the excitability. Moreover, after a 1-h pretreatment with FTY720 (an agonist for S1PR1/R3/R4/R5),
neither SEW2871 (S1PR1 selective agonist) nor S1P augmented the excitability. However, after pretreatment with
CYM-5442 (selective for S1PR1), SEW2871 was ineffective, but S1P increased the excitability of some, but not
all, sensory neurons.
Conclusions: These results demonstrate that the enhanced excitability produced by S1P is mediated by activation
of S1PR1 and/or S1PR3.
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Sphingosine-1-phosphate (S1P) is a bioactive lipid which
has been shown to exert important biological functions
in a variety of systems such as the immune and cardio-
vascular systems as well as in the regulation of cancer
cells [1-4]. S1P can function as a primary messenger to
act on a family of five G-protein-coupled receptors (S1P* Correspondence: gnicol@iupui.edu
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ies also demonstrate that S1P is involved in the sensation
and modulation of pain (reviewed by [7,8]). Previous work
from our laboratory demonstrated that extracellular deliv-
ery of S1P was capable of enhancing the excitability of
sensory neurons in a GDP-β-S-dependent manner [9].
Additional studies demonstrated that S1P activation
of S1PRs augmented both heat- and capsaicin-activated
membrane currents in mouse sensory neurons [10]. Appli-
cation of S1P increased the firing frequency of polymodal
C fibers in response to a thermal stimulus in a skin-nerveis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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sult of immune cell invasion [10]. Similarly, injection of
S1P into the rat’s hindpaw produced edema, which is a
hallmark of inflammation [11,12] as well as significant
thermal and mechanical hyperalgesia [10,13]. Recent
single-cell quantitative real-time PCR studies from our la-
boratory demonstrated that small-, medium-, and large-
diameter sensory neurons can express the mRNAs for all
five S1PRs wherein S1PR subtype 1 (S1PR1) was the high-
est expressor in greater than 50% of these isolated single
neurons [14].
To establish which S1PR mediated the enhanced excit-
ability produced by S1P, a study using short-interfering
RNA (siRNA) to selectively knockdown expression and
selective agonists demonstrated that S1PR1 plays a
crucial, but not exclusive, role in mediating neuronal
sensitization. Small-diameter sensory neurons treated
with siRNA targeted to S1PR1 were unresponsive to the
S1PR1 selective agonist SEW2871; however, treatment
with the more global agonist, S1P, was still capable of
increasing the excitability in approximately one third of
the siRNA-treated neurons [15]. Thus, these observa-
tions indicated that S1PR1 plays a prominent role in the
S1P-induced neuronal sensitization, but there must be
other S1P receptors capable of mediating the S1P-
induced enhancement of excitability. The studies de-
scribed below show that, in addition to S1PR1, activation
of S1PR3 can lead to the enhancement of excitability in
sensory neurons.
Methods
Isolation and maintenance of sensory neurons
Sensory neurons were harvested from young adult
Sprague–Dawley rats (80 to 150 g) and from young adult
mice on a C57BL/6 J background (Harlan Laboratories,
Indianapolis, IN, USA). Sensory neurons isolated from
the mouse were only used in the examination of mem-
brane currents activated by S1P. Briefly, male rats or
mice were killed by placing them in a chamber that was
then filled with CO2. Dorsal root ganglia (DRGs) were
isolated and collected in a conical tube with sterilized
Puck’s solution. The tube was centrifuged for 1 min at
approximately 2000 × g, and the pellet was resuspended
in 1 ml Puck’s solution containing 10 U of papain
(Worthington, Lakewood, NJ, USA). After a 15-min
incubation at 37°C, the tube was centrifuged at 2000 × g
for 1 min, and the supernatant was replaced by 1 ml
F-12 medium containing 1 mg collagenase IA and
2.5 mg dispase II (Roche Diagnostics, Indianapolis, IN,
USA). The DRGs were resuspended and incubated at
37°C for 20 min. The suspension was centrifuged for
1 min at 2000 × g, and the supernatant was removed.
The pellet was resuspended in F-12 medium supple-
mented with 10% heat-inactivated horse serum and30 ng/ml nerve growth factor (NGF) (Harlan Biopro-
ducts, Indianapolis, IN, USA) and mechanically dissoci-
ated with a fire-polished glass pipette until all visible
chunks of tissue disappeared. Isolated cells were plated
onto plastic coverslips previously coated with 100 μg/ml
poly-D-lysine and 5 μg/ml laminin. Cells were main-
tained in culture at 37°C and 3% CO2 for 18 to 24 h be-
fore electrophysiological recording. All procedures have
been approved by the Animal Use and Care Committee
of the Indiana University School of Medicine.
Electrophysiology
Recordings were made using the whole-cell patch-clamp
technique as previously described [16]. Briefly, a cover-
slip with sensory neurons was placed in a recording
chamber filled with normal Ringer’s solution of the fol-
lowing composition (in mM): 140 NaCl, 5 KCl, 2 CaCl2,
1 MgCl2, 10 4-(2-Hydroxyethyl)piperazine-1-ethanesul-
fonic acid (HEPES), and 10 glucose, with pH adjusted to
7.4 using NaOH. Recording pipettes were pulled from
borosilicate glass tubing (Model G85165T-4, Warner In-
struments, Hamden, CT, USA). Recording pipettes had
resistances of 2 to 5 MΩ when filled with the following
solution (in mM): 140 KCl, 5 MgCl2, 4 ATP, 0.3 GTP,
0.25 CaCl2, 0.5 EGTA (calculated free Ca
2+ concentra-
tion of 100 nM, MaxChelator), and 10 HEPES, at pH 7.2
adjusted with KOH. Whole-cell voltages or currents
were recorded with an Axopatch 200 or Axopatch 200B
amplifier (Molecular Devices, Sunnyvale, CA, USA).
Data were acquired and analyzed with pCLAMP 10
(Molecular Devices, Sunnyvale, CA, USA). All drugs
were applied with a VC-8 bath perfusion system (Warner
Instruments, Hamden, CT, USA) unless otherwise noted.
In the current-clamp experiments, the neurons were held
at their resting potentials (between −45 and −65 mV), and
a depolarizing current ramp (1,000 ms in duration) was
applied. The amplitude of the ramp was adjusted to pro-
duce between 2 and 4 action potentials (APs) under con-
trol conditions and then the same ramp was used
throughout the recording period for each individual
neuron. Voltages were filtered at 5 kHz and sampled at
2 kHz. In voltage-clamp recordings, neurons were held
at −60 mV. Currents were filtered at 5 kHz and sampled
at 500 Hz. Additionally, the voltage-clamp recordings
were digitally filtered after acquisition using a low-pass
8-pole Bessel filter function (60 Hz −3 dB cutoff) in
Clampfit. At the end of each recording, the neuron was
exposed to 1 μM capsaicin. This neurotoxin was used to
distinguish capsaicin-sensitive sensory neurons as these
neurons are believed to transmit nociceptive information
[17]. However, the correlation between capsaicin sensitiv-
ity and that a neuron is a nociceptor is not absolute. Some
nociceptive neurons are insensitive to capsaicin and
some capsaicin-sensitive neurons are not nociceptors [18].
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small-diameter sensory neurons that could serve a noci-
ceptive function. All results presented in this report were
obtained from capsaicin-sensitive neurons, unless other-
wise stated. All experiments were performed at room
temperature, approximately 23°C.
siRNA treatment
The gene sequences of S1PR2 and S1PR3 were obtained
from NCBI with the accession numbers NM_017192
and XM_225216, respectively. siRNAs targeting S1PR2
and S1PR3 were designed by the online tool provided by
the Whitehead Institute for Biomedical Research, Cam-
bridge, MA (http://sirna.wi.mit.edu) [19] and synthesized
by Thermo Scientific (Waltham, MA, USA). Both siR-
NAs were labeled with the fluorescent tag, fluorescein,
with 3′-end modification. For the siRNA targeted to
S1PR2, the sense strand was 5′-CCUUCUGGUGCUAA
UCGCAUU-3′, and the antisense strand was 3′-UUGG
AAGACCACGAUUAGCGU-5′. For the siRNA targeted
to S1PR3, the sense strand was 5′-CAUUCUGAUG
UCCGGUAGGUU-3′, and the antisense strand was 3′-UU
GUAAGACUACAGGCCAUCC-5′. The siRNA targeted to
S1PR1 was the same sequence as described in [15] and la-
beled with the fluorescent tag DY547. A universal Silencer
Negative Control #1 siRNA (cat #4390843, Ambion, Grand
Island, NY, USA) was used as the negative control.
Neurons isolated from the rat DRG were maintained
in culture in F-12 medium with 30 ng/ml NGF at 37°C
for 24 h. F-12 was replaced with Opti-MEM medium
(Life Technologies, Grand Island, NY, USA), and the
neurons were incubated at 37°C for about 5 h for lipid
transfection. The transfection reagent, metafectene
(Biontex-USA, San Diego, CA, USA) and siRNA com-
plex (5 μl, 100 nM) were prepared in 2 ml Opti-MEM.
Neurons were exposed to either siRNA, negative control
siRNA, or metafectene alone and maintained at 37°C for
48 h. F-12 medium was used to wash out the metafec-
tene and the siRNA; neurons were then maintained in F-
12 medium with 10% heat-inactivated horse serum and
30 ng/ml NGF. Neurons were incubated for an add-
itional 48 h before real-time quantitative PCR (qPCR) or
patch-clamp experiments were performed.
cDNA generation from siRNA-treated cells
Sensory neurons that had undergone siRNA treatments
were collected for real-time qPCR measurements. The
F-12 medium was aspirated from the cell-culture dish,
and neurons were washed with PBS solution. Total RNA
from the cells was extracted by using the RNeasy Plus
Mini Kit (Qiagen, Valencia, CA, USA), following the
manufacturer’s instructions. The concentration of each
individual RNA from different treatments was measured
with a NanoDrop ND-1000 Spectrophotometer (ThermoScientific, Waltham, MA, USA). To eliminate contamin-
ation by genomic DNA, 500 ng of RNA was treated with
1 μl DNase I (Invitrogen, cat. #18068-015) in a 10-μl re-
action at room temperature for 15 min. The reaction
was terminated by adding 1 μl 25 mM ethylenedinitrilo-
tetraacetic acid (EDTA), and the reaction mixture was
incubated at 65°C for 10 min. To generate cDNA from
RNA, the DNase-I-treated RNA template was mixed
with 1 μl iScript reverse transcriptase in a 20-μl reaction
(iScript cDNA Synthesis Kit cat #170-8891, Bio-Rad,
Hercules, CA, USA). The reaction protocol was as
follows: 25°C for 5 min, 42°C for 30 min, and 85°C for
5 min.Pre-amplification of cDNA from siRNA-treated cells
A 0.5X pooled assay mix was prepared by adding 2 μl of
20X TaqMan® Gene Expression Assay for each gene of
interest (GOI) to Tris-EDTA (TE) buffer pH 8.0, final
volume 80 μl. All Gene Expression Assays are labeled
with the reporter dye FAM, except for hypoxanthine
phosphoribosyltransferase 1 (HPRT) which was labeled
with the reporter dye VIC. To each 1 μl (25 ng) of
cDNA, 5 μl of 2X Pre-amp Master Mix (Life Technolo-
gies, Grand Island, NY, USA, cat #4391128), 1 μl of 0.5X
pooled assay mix, and 3 μl nuclease-free H2O (Ambion,
cat #9932) were added. After a 10-min incubation at 95°
C, 14 cycles of 95°C/15 s and 60°C/4 min were run,
followed by storage at −20°C.TaqMan quantitative qPCR
The pre-amplified cDNA was diluted fivefold with
nuclease-free H2O, and 2.5 μl of the dilution was used
as the template in a 10-μl qPCR reaction also containing
5 μl 2X Taqman Gene Expression Master Mix (Applied
Biosystems, Waltham, MA, USA, cat #4369514), 0.5 μl
20X TaqMan GOI Assay, and 2 μl nuclease-free water.
A positive control template was 25 ng of pooled rat lung
cDNA. Reactions were run in triplicate on a 7500 Fast
Real-Time PCR System (Applied Biosystems, Waltham,
MA, USA). The thermal-cycling condition was 95°C for
10 min followed by 40 cycles of 95°C for 15 s and 60°C
for 1 min. The quantification cycle (Cq) values of vari-
ous GOIs were obtained at the threshold where the
value of normalized fluorescence emission generated by
FAM or VIC (ΔRn) reached 0.3. The expression of dif-
ferent genes was calculated based on the number of cop-
ies of each gene where Number of Copies = (Primer
Efficiency)−Cq. The relative expression of the GOI was
determined by dividing the average copy number of the
GOI by that of the reference genes, acidic ribosomal
phosphoprotein P0 (Arbp) or HPRT. Efficiencies of each
primer pair were determined from the slope of a seven-
point standard curve (details described in [14]).
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Data are presented as the means ± standard error of the
mean (SEM). Statistical differences in the mRNA expres-
sion levels between the control groups and the treatment
groups were determined by either Student’s t-test or an
analysis of variance (ANOVA). Statistical differences
between the control recordings and those obtained
under various treatment conditions were determined by
either an ANOVA or a repeated measures (RM) ANOVA
whenever appropriate. When a significant difference
was obtained with an ANOVA, post hoc analyses were
performed using a Holm-Sidak all-pairs test. If the data
set failed the normality test, a Kruskal-Wallis one-way
ANOVA on ranks was performed, followed by a Tukey
or Dunn’s all pairwise test. The results were considered
statistically significant when the P value was <0.05 (SigmaStat
3.5 software).
Chemicals
F-12 Nutrient Mixture (Gibco Catalog # 21700–075)
was supplemented with the following per liter: 1.18 g
NaHCO3 (Sigma cat # S6014), 1X (2 mM) L-glutamine
(Gibco cat # 25030–081), 50 units penicillin-50 mg/ml
streptomycin (Gibco cat #15070-063), 10% heat-inactivated
horse serum (Gibco cat #26050-088), 9 μg/ml 5-fluoro-2′-
deoyuridine (Sigma cat # F-0503), and 21 μg/ml uridine
(Sigma cat #U-3750). S1P and VPC 23019 were obtained
from Avanti Polar Lipids (Alabaster, AL, USA); S1P was
dissolved according to the manufacturer’s instructions
(http://www.avantilipids.com/index.php?option=com_content&
view=article&id=1114&Itemid=173&catnumber=860492). Pros-
taglandin E2 (PGE2), W146, FTY720, sphingosine kinase
inhibitor II (SKI-II), SEW2871, and CAY10444 were pur-
chased from Cayman Chemical (Ann Arbor, MI, USA).
CYM-5442 was purchased from Tocris Bioscience (Bristol,
UK). VPC 44116 was a generous gift from Dr. Kevin R.
Lynch, University of Virginia. All other chemicals were ob-
tained from Sigma-Aldrich (St. Louis, MO, USA). PGE2,
W146, FTY720, SKI-II, SEW2871, CAY10444, VPC 23019,
and VPC 44116 were dissolved in 1-methyl-2-pyrrolidinone
(MPL). The MPL stock solutions were then diluted with
Ringer’s solution to yield the appropriate concentrations.
The vehicle, MPL was typically used at 1,000- to 5,000-fold
dilutions. Our earlier studies demonstrated that MPL does
not affect the potassium or sodium currents in the DRG
sensory neurons [9,20].
Results
siRNAs effectively and specifically knock down S1PR
expression
Our previous studies demonstrated that S1PR1 played a
predominate, but not exclusive, role in augmenting the
excitability of rat sensory neurons [15]. These results
raise the question as to which other S1PRs contribute tothe S1P-mediated sensitization. The existing literature
indicates that in other model systems as well as in the
nervous system S1PR1, R2, and R3 play important al-
though varied roles in modulating cellular function;
however, the impact of S1PR4 and R5 are poorly under-
stood. To explore the idea that S1PR1, R2, and R3 are
key players in the S1P-mediated sensitization, siRNA tar-
geted to these S1PRs were designed and their ability to
reduce the expression of their respective receptor was
measured by qPCR. Our previous results showed that
siRNA targeted to S1PR1 reduced its expression by about
75% [15]; this siRNA was used in experiments described
below. Treatment with siRNAs (100 and 200 nM) targeted
to S1PR2 or R3 significantly reduced the levels of mRNA
compared to naïve untreated neurons by approximately
80% and 70%, respectively (see Figure 1A,B). Treatment
with the transfecting detergent, metafectene, or the nega-
tive control siRNA had no significant effect on the mRNA
levels for either S1PR2 or R3. In addition, siRNA targeted
to either S1PR2 or R3 did not have any off-target effects
on the expression levels of S1PR1 (see Figure 1C). In order
to determine the potential contributions of multiple
S1PRs to neuronal sensitization, the siRNAs targeted to
S1PR1, R2, and R3 were pooled (100 nM each) to assess
their knockdown of the mRNA levels for these individual
receptors as well as their possible off-target effects. The
combination of S1PR1, R2, and R3 siRNAs reduced the
mRNAs for S1PR1, R2, and R3 by 62%, 74%, and 76%, re-
spectively, compared to untreated neurons (see Figure 2A,
B,C, respectively) and had no off-target effects. The pooled
siRNAs were as equally effective as the individual siRNAs
for S1PR2 and R3 (panels B and C of Figure 2). For ex-
ample, in Figure 2C, the pooled siRNAs (100 nM each) re-
duced the mRNA levels of S1PR3 by 76%, and the single
siRNA to S1PR3 (200 nM) reduced S1PR3 mRNA by
72%. As shown in Figure 2D, neither the pooled siRNAs
nor the individual siRNAs targeted to S1PR2 or R3 af-
fected the mRNA levels of S1PR4 and R5. Similar results
were obtained when the mRNA levels were assessed
relative to the reference gene HPRT (data not shown).
Taken together, these results indicate that the siRNAs
targeting S1PR1, R2, or R3 specifically reduced the mRNA
expression of their respective receptor and have no off-
target actions.
Pooled siRNAs targeted to S1PR1/2/3 or S1PR1/3 block the
S1P-induced increase in excitability
Having validated the specificity of these siRNAs, the
functional contributions of S1PRs to the S1P-induced
enhancement of neuronal excitability were examined. As
shown in the representative traces in Figure 3A, after
treatment of sensory neurons with the pool of siRNAs
targeted to S1PR1/2/3 (100 nM each), the ramp of current
evoked only 4 APs after a 6-min exposure to 1 μM S1P
Figure 1 siRNAs targeted to S1PR2 or R3 specifically knockdown the mRNA levels for their respective receptors. (A) 100 and 200 nM siRNA
targeted to S1PR2 significantly reduced the mRNA levels of S1PR2 by 79.8% ± 3.1% and 77.1% ± 6.4%, respectively, compared to the untreated
control values. There was no difference between the knockdown values for 100 and 200 nM siRNA treatments. The different treatment groups
(Cont - untreated control, Meta - metafectene alone, NC - negative control siRNA, and siRNA targeted to the S1PR) were normalized to their
respective untreated control values. (B) 100 and 200 nM siRNA targeted to S1PR3 significantly reduced the mRNA levels of S1PR3 by 64.5% ± 7.3%
and 70.2% ± 6.3%, respectively, compared to the untreated control values. There was no difference between the knockdown values for 100 and
200 nM siRNA treatments. (C) siRNA targeted to S1PR2 (200 nM) or S1PR3 (200 nM) does not alter the mRNA levels of S1PR1 (P = 0.88). (A-C)
values were obtained from neurons isolated from five different tissue harvests; a Pfaffl analysis [70] was used to quantify the values of receptor
mRNA relative to the reference gene, Arbp, for the different treatments; a Kruskal-Wallis ANOVA with a Tukey post hoc test was used to
determine statistical differences between the different groups where the asterisks indicate P < 0.05. S1PR - sphingosine-1-phosphate receptor,
siRNA - short-interfering RNA.
Li et al. Journal of Neuroinflammation  (2015) 12:70 Page 5 of 20(right panel) compared to 3 APs for the control condi-
tions (left panel). In contrast, after treatment with 300
nM negative control (NC) siRNA, a 6-min exposure to
1 μM S1P increased the number of APs from a control
value of 4 APs (Figure 3B, left panel) to 10 APs (right
panel). The results obtained from a total of five neurons
in each treatment group are summarized in Figure 3C.
Exposure to 1 μM S1P significantly increased the num-
ber of APs in NC siRNA-treated neurons at both 6 and
10 min compared to the control values (P = 0.003, RM
ANOVA Holm-Sidak all-pairs test) and is similar to our
previous reports obtained from untreated sensory neu-
rons [9,15]. However, S1P failed to augment AP firing in
those neurons treated with the pooled siRNAs (P = 0.47).
These results indicate that S1P can sensitize sensory
neurons through the activation of S1PR1, R2, and/or R3
and that R4 and R5 are not sufficient to mediate the
S1P-induced sensitization.
Previously, we demonstrated that S1PR1 plays a prom-
inent, but not exclusive, role in the sensitization medi-
ated by S1P [15]. In addition, to examine the role of
S1PR2, we used a putative S1PR2-specific antagonist
JTE-013; surprisingly, JTE-013 itself increased the excit-
ability of sensory neurons through an as-yet-to-be-de-
fined G-protein-coupled receptor (GPCR) [21]. Thus, to
distinguish a possible role for S1PR2 in the S1P-induced
sensitization, sensory neurons were treated with a com-
bination of siRNAs targeted to S1PR1 and R3 (100 nM
each). As shown in Figure 4, under control conditions, a
representative neuron generated 3 APs in response tothe current ramp (Figure 4A), and after a 10-min exposure
to 1 μM S1P, the ramp evoked 2 APs (Figure 4B). As a posi-
tive control, neurons were exposed to pro-inflammatory
PGE2 to confirm that these neurons were capable of
sensitization (via a Gs/cAMP/PKA pathway) [22-24]. After
a 10-min exposure to 1 μM PGE2, the ramp evoked 13
APs (Figure 4C). As summarized in Figure 4D, S1P failed
to enhance the excitability after treatment with siRNAs
targeted to S1PR1 and R3, suggesting that S1PR1 and/or
R3, but not R2, mediates the sensitization produced by
S1P. In contrast, PGE2 significantly increased the AP firing
at 14, 16, and 20 min compared to both the control and
S1P treatment conditions (P < 0.001, ANOVA Holm-Sidak
all-pairs test). Taken together, these results demonstrate
that the S1P-induced sensitization is mediated through
S1PR1 and/or R3 while R2, R4, and R5 appear to have no
significant role.
The selective S1PR3 agonist, CYM-5541, sensitizes
sensory neurons
Our results suggest that S1PR3 can lead to the sensitization
of sensory neurons. To test that idea directly, the re-
cently discovered selective agonist of S1PR3, CYM-5541,
was used [25]. In Chinese hamster ovary cells (CHOs)
stably expressing S1PRs, the half-maximal effective con-
centration (EC50) values for CYM-5541 activation of
S1PR3 was 105 nM and for S1PR1 it was approximately
33 μM, and there was no activity at S1PR2/4/5 for concen-
trations as high as 50 μM [25]. We found that CYM-5541
in a time- and concentration-dependent manner lead to
Figure 2 siRNAs targeted to S1PR1, R2, and R3 specifically knockdown receptor expression. (A) Combined short-interfering RNAs (siRNAs) targeted
to S1PR1/R2/R3 (100 nM each) significantly reduced the mRNA expression of S1PR1 by 61.6% ± 2.9% compared to the untreated control (Cont).
The levels of S1PR1 mRNA were not affected by treatment with metafectene (Meta), 200 nM of the negative control siRNA (NC), 200 nM siRNA
targeted to S1PR2 (R2), or 200 nM siRNA targeted to S1PR3 (R3). The different treatment groups were normalized to their respective untreated
controls. (B) Combined siRNAs targeted to S1PR1/R2/R3 (100 nM each) and siRNA targeted to S1PR2 (200 nM) alone significantly reduced the
expression of S1PR2 mRNA by 74.3% ± 3.2% and 68.5% ± 2.6%, respectively. (C) Combined siRNAs targeted to S1PR1/R2/R3 (100 nM each) and
siRNA targeted to S1PR3 (200 nM) alone significantly reduced the expression of S1PR3 mRNA by 76.3% ± 3.5% and 72.1% ± 1.5%, respectively.
(D) The combined siRNAs targeted to S1PR1/R2/R3 did not significantly affect the mRNA levels of either S1PR4 or R5 (P = 0.88 and 0.20, respectively,
ANOVA). (A-D) Values were obtained from neurons isolated from four different tissue harvests; a copy number analysis (see Kays et al. [14]) was
used to quantify the values of receptor mRNA relative to the reference gene, Arbp, for the different treatments; a Kruskal-Wallis ANOVA with a
Tukey post hoc test was used to determine statistical differences between the different groups where the asterisks indicate P < 0.05.
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neurons. A representative recording (Figure 5A) shows
that, under control conditions, the depolarizing ramp
evoked 3 APs whereas, after a 10 min exposure to
10 μM CYM-5441, 11 APs were generated. The time-and concentration-dependence for the actions of CYM-
5441 are summarized in Figure 5B. Exposure to 100 nM
CYM-5541 failed to alter AP firing (n = 5, P = 0.80
RM ANOVA) or the resting membrane potential (see
Table 1) over a 10-min recording period. Both 1 and
Figure 3 Combined siRNAs targeted to S1PR1/R2/R3 blocked the S1P-induced increase in excitability. (A) shows representative traces from a
neuron treated with the combined short-interfering RNAs (siRNAs) targeted to sphingosine-1-phosphate (S1P)R1/R2/R3 (100 nM each); the trace
shown in the left panel was obtained under control conditions whereas that in the right panel was after a 6-min exposure to 1 μM S1P. The
dotted lines indicate the 0 mV level. (B) illustrates cells treated with 300 nM negative control siRNA. The left panel shows that under control
conditions 4 action potentials (APs) were fired whereas, after a 6-min exposure to 1 μM S1P, the same ramp current elicited 10 APs. (C) summarizes
the results obtained from five cells in each treatment group. S1P significantly increased the number of APs in neurons treated with negative control
(NC) siRNA at 6 and 10 min. The asterisks (*) represent a significant difference compared to the control (P < 0.05 RM ANOVA with a Holm-Sidak
all-pairs test).
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6- and 10-min exposures compared to their respective
controls. However, neither of these concentrations of
CYM-5541 depolarized the resting membrane potential
(see Table 1). In addition, neither the resting membrane
potential (−58.5 ± 1.7 mV control vs. −57.9 ± 3.0 mV
CYM-5541 after 10 min, n = 7, P = 0.89 ANOVA, data
not shown) nor the enhanced excitability produced by
10 μM CYM-5541 were affected by a 30-min pretreat-
ment with 1 μM W146, a S1PR1 selective antagonist (in-
hibition constant (Ki) 70 to 80 nM) [26] (see Figure 5B).
These results demonstrate that at 10 μM, CYM-5541
was capable of augmenting AP firing without changing
the resting membrane potential through the activation
of S1PR3. Figure 5C summarizes the concentrationrelation for the fold increase in APs generated at 10 min
normalized to the number of APs obtained for their re-
spective untreated control recordings; these results
show that 10 μM CYM-5541 produces about a 2.5-fold
increase in the number of evoked APs through the acti-
vation of S1PR3. To determine the maximal response,
neurons were then exposed to 30 μM CYM-5541; sur-
prisingly, this led to a rapid and large depolarization
that was accompanied by a large number of APs (see
Figure 5D). The left panel illustrates a 200-s recording
of the resting membrane potential under normal control
conditions (−51 mV) wherein there is a complete lack
of any spontaneous AP activity; the right panel shows
that, in this neuron, exposure to 30 μM CYM-5541
(duration 30 to 150 s) depolarized the membrane
Figure 4 Neurons treated with siRNAs targeted to S1PR1 and R3 were not sensitized by S1P but did respond to PGE2. (A) demonstrates
representative traces from a sensory neuron treated with combined siRNAs targeted to S1PR1 and R3 (100 nM each); under control conditions,
the neuron generated 3 APs. (B) After a 10-min exposure to 1 μM S1P, this neuron fired only 2 APs. (C) A subsequent 10-min exposure to 1 μM
PGE2 resulted in the generation of 13 APs. (D) summarizes the effects of S1P and PGE2 exposures after treatment with siRNAs targeted to S1PR1
and R3. S1P failed to augment AP firing, but PGE2 significantly increased the number of APs after 14-, 16-, and 20-min exposures. Results were
obtained from eight neurons (control through 12 min), seven neurons at 14 min, and six neurons at 16 and 20 min. Asterisks (*) represent a
significant difference between those treatments compared to control (P < 0.05, Kruskal-Wallis ANOVA on ranks with Dunn’s post hoc test). AP - action
potential, Cont - control, PGE2 - prostaglandin E2, S1P - sphingosine-1-phosphate.
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spontaneous APs. In nine neurons, 30 μM CYM-5541
lead to an average depolarization of approximately 37 ±
3 mV (see Table 1). In four neurons, the recovery from
the CYM-5541-induced depolarization was examined.
After a 20-min washout with normal Ringers, the mem-
brane potential had recovered by 40% ± 17% (range 4%
to 82%). It is possible that this high concentration of
CYM-5541 depolarizes the neuronal membrane through
activation of S1PR1 rather than R3 as the EC50 for CYM-
5541 at S1PR1 is approximately 33 μM [25]. To test this
idea, sensory neurons were pretreated for 30 min with
either 1 or 10 μM W146. In the presence of W146,
30 μM CYM-5541 did not significantly depolarize the
resting membrane potential (see Table 1). In support of
CYM-5541 activation of S1PR1, exposure to 30 μM
SEW2871 (a selective S1PR1 agonist) produced a signifi-
cant depolarization (control −56.8 ± 1.2 mV vs. −33.0 ±
4.8 mV after SEW2871, n = 5, P = 0.007 paired t-test,
data not shown) that was associated with a largeincrease in spontaneous AP firing (see Figure 5E). These
results are similar to those obtained with CYM-5541.
Therefore, these results demonstrate that activation of
S1PR3 can augment AP firing without directly altering the
resting membrane potential; however, at the higher and
likely unphysiological concentrations, activation of S1PR1
by either SEW2871 or CYM-5441 can produce a large
depolarization accompanied by extensive AP firing.
Together, selective antagonists to S1PR1 and R3 abolish
the S1P-induced sensitization
To corroborate the siRNA findings, specific antagonists
were used to block receptor function: W146, a selective
S1PR1 antagonist, and CAY10444 (BML-241), a selective
S1PR3 antagonist. Although most studies indicate that
CAY10444 is a low-potency antagonist of S1PR3 [27-29],
a few studies have suggested that this compound lacks
specificity [30-32]. CAY1044 (50 μM) has been reported
to completely block the S1P-induced increase in intra-
cellular Ca2+ in keratinocytes [28]; consistent with this
Figure 5 A selective agonist of S1PR3, CYM-5541, sensitizes AP firing. (A) Left panel illustrates a representative recording where the ramp
evoked 3 APs under control conditions; right panel shows that after a 10-min exposure to 10 μM CYM-5441, 11 APs were generated. The dotted
line indicates 0 mV. (B) the time- and concentration-dependence of CYM-5541 on the number of evoked APs over a 10-min recording period.
For 100 nM, there was no effect on the number of evoked APs (n = 5, P = 0.80 RM ANOVA); for 1 μM, the increase in AP number at 6 and 10 min
was significantly different than the control (n = 6, P = 0.002 RM ANOVA Friedman test on ranks); for 10 μM, the increase at 6 and 10 min was
significantly different than the control (n = 6, P < 0.001 Kruskal-Wallis ANOVA on ranks Dunn’s test); for the 1 μM W146 + 10 μM CYM-5541, the
increase at 6 and 10 min was significantly different than the control (n = 7 for control, 2 and 6 min, n = 6 for 10 min, P < 0.001 ANOVA Holm-Sidak
all-pairs test). The AP values for 10 μM CYM-5541 and 1 μM W146 + 10 μM CYM-5541 at either 6 or 10 min were not different (P > 0.05 ANOVA).
(C) Concentration dependence for the normalized fold increase in the number of APs measured after a 10-min exposure to CYM-5541. (D) Recording
of membrane potential where the left panel shows the control condition; the right panel shows exposure to 30 μM CYM-5541 (30 to 150 s represented
by the bar). (E) Depolarization produced by 30 μM SEW2871 (application 30 to 150 s). Recordings were acquired at 5 kHz; traces are reproduced at
0.5 kHz. Scale bars apply to all three panels. AP - action potential, Cont - control.
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crease in Ca2+. Using a GPCR-β arrestin assay, CAY10444
suppressed the activation of S1PR3 with an IC50 value of
approximately 5 μM [29]. In MCF-7 Neo cells, treatment
with S1P produced a significant increase in the phosphor-
ylation of ERK1/2; this increase was greatly suppressed by
similar extents after exposure to either 10 μM CAY1044
or siRNA knockdown of S1PR3 [33]. In addition, S1P pro-
duced a relaxation of contracted coronary artery, which
was significantly attenuated by treatment with 10 μM
CAY10444 but was unaffected by W146 [34]. In contrast
to the above, Jongsma et al. reported that in Flp-In-CHO
cells, S1P increased intracellular Ca2+ and that treatmentwith 10 μM CAY10444 produced a rightward shift of
about tenfold in the EC50 value for the mobilization of
Ca2+ [30]. However, the EC50 values for the increases in
intracellular Ca2+ produced by ATP activation of P2 recep-
tors and phenylephrine activation of α1-adenoreceptors
were also right-shifted by 10 μM CAY10444, although the
shifts were smaller than that for S1P. Also, CAY10444 did
not affect the S1P-mediated decrease in forskolin-elevated
levels of cyclic AMP, suggesting that CAY10444 lacked spe-
cificity for S1PR3. The differences in these results have yet
to be resolved.
To examine the role of S1PR1 and S1PR3, we found
that a 30-min pretreatment with 1 μM W146 and 10 μM






100 nM −55.5 ± 2.4 −52.8 ± 1.9 5
1 μM −53.9 ± 1.0 −50.5 ± 1.8 6
10 μM −51.6 ± 1.0 −48.1 ± 1.8 6
30 μM −55.5 ± 1.8 −18.6 ± 2.9* 9
1 μM W146 + 30 μM −61.7 ± 2.5 −52.0 ± 5.6 4
10 μM W146 + 30 μM −52.9 ± 1.2 −47.8 ± 4.0 3
*P < 0.05 paired t-test; n = number of neurons.
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after exposure to 1 μM S1P (see Figure 6A, n = 10). In a
separate series of experiments, treatment with W146
and CAY1044 did not alter the capacity of 1 μM PGE2
to significantly increase AP firing (see Figure 6B, n = 4
to 7). These results are consistent with our observations
obtained with siRNAs targeted to S1PR1 and R3 and in-
dicate that S1PR1 and/or R3, but not S1PR2, R4 or R5, is
necessary for S1P-induced sensitization.VPC 23019 and VPC 44116, antagonists at both S1PR1
and R3, block S1P-induced sensitization
The S1PR1/R3 antagonist, VPC 23019, was used to fur-
ther examine the role of S1PR1 and R3 in the S1P-
induced sensitization. VPC 23019 has Ki values of
approximately 25 and 300 nM for S1PR1 and R3, re-
spectively, and is also a partial agonist for S1PR4 and R5
(EC50 values of 120 and 480 nM, respectively) [35-37].Figure 6 W146, a selective S1PR1 antagonist, and CAY10444, a selective S1
not PGEx2. (A) Pretreatment with 1 μM W146 and 10 μM CAY10444 for 30
obtained from ten sensory neurons (P = 0.15 Friedman RM ANOVA on rank
CAY10444 for 30 min blocked the sensitization produced by 1 μM S1P; how
number of evoked APs (n = 7 control through 12 min, n = 6, 5, and 4 for 14
difference compared to the 10-min S1P results (P < 0.05 Kruskal-Wallis ANO
were not different from the control values. AP - action potential, Cont - coControl recordings indicated that exposure to 1 μM
VPC 23019 did not change the number of APs in sen-
sory neurons over a 15-min recording period (control
3.8 ± 0.3 APs vs. 15-min VPC 23019 4.3 ± 0.9 APs, n = 4,
P = 0.59 RM ANOVA, data not shown). As shown in
Figure 7A, a 30-min pretreatment with 1 μM VPC
23019 completely blocked the sensitizing actions of 100
nM SEW2871 (a selective S1PR1 agonist) and 1 μM S1P
(the more global receptor agonist). In a separate group
of sensory neurons, pretreatment with 1 μM VPC 23019
suppressed the enhanced excitability produced by 1 μM
S1P but had no effect on the sensitization produced by
1 μM PGE2 (see Figure 7B). To corroborate the role of
S1PR1 and R3 in augmenting neuronal excitability, the
phosphonate analog of VPC 23019, VPC 44116, was also
used. VPC 44116 is a potent antagonist at both S1PR1
and R3 (Ki values of 30 and 300 nM, respectively) and
also a partial agonist for S1PR4 and R5 (EC50 values of
6100 and 33 nM, respectively) [36]. Neither VPC 23019
nor VPC 44116 have any effects at S1PR2 [32-34]. Simi-
lar to VPC 23019, exposure to 1 μM VPC 44116 did not
alter the number of evoked APs over a 15-min recording
period (control 3.0 ± 0.4 APs vs. 15-min VPC 44116 3.8
± 0.6 APs, n = 4, P = 0.28 RM ANOVA, data not shown).
A 30-min pretreatment with 1 μM VPC 44116 blocked
the increase in excitability caused by 1 μM S1P but had
no effect on the sensitization produced by 1 μM PGE2
(see Figure 7C). Thus, these results demonstrate that the
enhanced excitability produced by S1P is mediated by
activation of S1PR1 and/or R3 and that S1PR2, R4, or R5
do not contribute to the enhanced excitability produced
by S1P in sensory neurons.PR3 antagonist, together abolished the sensitizing effect of S1P, but
min blocked the sensitization produced by 1 μM S1P. Results were
s). (B) In another series of experiments, pretreatment with W146 and
ever, subsequent exposure to 1 μM PGE2 significantly increased the
, 16, and 20 min, respectively). The asterisks (*) represent a statistical
VA on ranks followed by Dunn’s post hoc test). The 10-min S1P results
ntrol, PGE2 - prostaglandin E2, S1P - sphingosine-1-phosphate.
Figure 7 (See legend on next page.)
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Figure 7 VPC 23019 and VPC 44116, S1PR1/R3 antagonists and S1PR4/R5 agonists, block S1P-induced sensitization. (A) A 30-min pretreatment
with 1 μM VPC 23019 blocked the capacity of 100 nM SEW2871 (SEW), a selective sphingosine-1-phosphate (S1P)R1 agonist, and 1 μM S1P, the
more global agonist, to augment action potential (AP) firing in sensory neurons (P = 0.87, RM ANOVA). In contrast, in untreated neurons, SEW2871
significantly increased the number of evoked APs after only a 4-min exposure (n = 7, P < 0.001, Friedman RM ANOVA with Tukey post hoc test)
although the number of evoked APs after S1P was not different from that with SEW2871. (B) In a different set of experiments, a 30-min pretreatment
with 1 μM VPC 23019 blocked the sensitization produced by 1 μM S1P; however, exposure to 1 μM PGE2 significantly increased the AP firing (P < 0.05
compared to control, ANOVA followed by Holm-Sidak all-pairs test). (C) A 30-min pretreatment with 1 μM VPC 44116 blocked the sensitization
produced by 1 μM S1P; however, subsequent expose to 1 μM PGE2 significantly increased the number of evoked APs compared to control
(represented by asterisks (*)) as well as the number of APs measured at 10-min S1P (represented by #)(n = 5, P < 0.001, RM ANOVA with Holm-Sidak
all-pairs test). Cont - control.
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increases excitability, but prolonged exposure blocks the
S1P-mediated sensitization
FTY720 (fingolimod) is a structural analog of sphingo-
sine that upon phosphorylation by sphingosine kinase 2
[38-42] has high affinities for all S1PRs except S1PR2
[38,43,44]. Receptor binding and functional assays indi-
cated that FTY720-P has EC50 values of approximately
0.3 to 0.6 nM for S1PR1, R4, and R5 and approximately 3
nM for R3 but has no activity at S1PR2. Thus, FTY720
can act as a potent agonist for specific S1PRs. However,
additional studies demonstrated that prolonged incuba-
tion with FTY720 resulted in the internalization and
degradation of both S1PR1 [45-49] and R3 [50-53], which
in effect removes these receptors from further activa-
tion/signaling (but see [49]). Therefore, such pharmaco-
logical agents capable of receptor activation with their
consequent internalization and degradation have been
termed functional antagonists. In this capacity, FTY720-
P acts as a suppressor of neuroinflammation and has
been approved for the treatment of relapsing-remitting
multiple sclerosis [44,54,55]. To further explore the roles
of S1PRs in neuronal sensitization, the capacity of
FTY720 to act as a functional antagonist was utilized.
As expected of a functional antagonist, acute treat-
ment with 100 nM FTY720 produced a significant
increase in the excitability of sensory neurons. A repre-
sentative recording is shown in Figure 8A where 4 APs
were evoked by the current ramp under control condi-
tions (left panel); however, after a 15-min exposure to
100 nM FTY720, the ramp now evoked 12 APs (right
panel) and depolarized the resting membrane potential
from −52 to −28 mV. Similar to our previous findings
obtained for SEW2871 [15], a selective S1PR1 agonist,
sensory neurons were either sensitive or insensitive to
FTY720; these results are summarized in Figure 8B. In
recordings from 13 neurons, 8 were significantly sensi-
tized after exposure to 100 nM FTY720, exhibiting about
a threefold increase in the number of evoked APs after
15- and 20-min exposures. Associated with the increased
AP firing, the resting membrane potential was also sig-
nificantly depolarized from a control value of −54.2 ± 1.2to −39.3 ± 4.3 mV after a 15-min exposure (data not
shown, P < 0.001 RM ANOVA, Holm-Sidak all-pairs
test). With FTY720-P, the time to reach a significant in-
crease in the number of APs was 15 min which is in
contrast to SEW2871 or S1P wherein the time to reach
a significant increase in the number of APs typically oc-
curred between 4 and 6 min [9,15]. This delay may well
reflect the fact that FTY720 must be phosphorylated by
sphingosine kinase 2 and then transported extracellularly
(see [56]) where it can function as an agonist at S1PRs
(but not S1PR2). In contrast, 5 of the 13 neurons were
insensitive to FTY720 wherein the number of APs
evoked after a 15-min exposure was not different than
the control values (control 2.6 ± 0.4 APs vs. 15-min ex-
posure 3.0 ± 0.7 APs, P = 0.80 Kruskal-Wallis ANOVA).
In these FTY720-insensitive neurons, the resting mem-
brane potential was not changed after exposure to
FTY720 (data not shown, control −58.8 ± 4.4 mV vs.
15-min exposure −58.5 ± 4.6 mV, P = 0.98 Kruskal-Wallis
ANOVA). Exposure to either 10 or 30 nM FTY720 failed
to increase the number of evoked APs in sensory neu-
rons during a 20-min recording period. For example,
under control conditions 3.6 ± 0.2 APs were evoked by
the current ramp, and after a 20-min exposure to 30 nM
FTY720, 4.4 ± 0.5 APs were generated (data not shown,
n = 5, P = 0.92 RM ANOVA). Previous studies indicated
that the actions of FTY720 were dependent upon phos-
phorylation by sphingosine kinase 2 [38-42]. To confirm
that phosphorylation was required for the sensitizing ac-
tions of FTY720, sensory neurons were pretreated for
30 min with 5 μM SKI-II, a specific inhibitor of sphingo-
sine kinases [57-59], and then exposed to 100 nM
FTY720. Inhibition of sphingosine kinases completely
blocked the ability of FTY720 to sensitize sensory neu-
rons (see Figure 8C). This result demonstrates that the
FTY720-induced increase in neuronal excitability de-
pends on the activity of sphingosine kinases.
The above results demonstrate that FTY720-P acutely
augments the excitability of sensory neurons; this finding
raises the question as to whether prolonged treatment
with this agonist can result in the internalization/degrad-
ation of S1PRs (except S1PR2) as expected of a functional
Figure 8 Acute FTY720 exposure increases neuronal excitability in a concentration- and time-dependent manner, but prolonged treatment blocks
sensitization. (A) shows a representative recording wherein 4 APs were evoked under control conditions (left) whereas, after a 15-min exposure to
100 nM FTY720, the number of evoked APs were increased to 12. The dotted lines indicate the 0 mV level. (B) summarizes the effects of 100 nM
FTY720 on sensory neurons. In one population, FTY720 significantly increased the number of APs after a 10-min exposure (n = 8), whereas another
population appeared to be insensitive to FTY720 (n = 5). (C) A 30-min pretreatment with 5 μM SKI-II, a selective inhibitor of sphingosine kinases,
blocked the capacity of 100 nM FTY720 to sensitize sensory neurons (n = 9 for the Cont-15 min and n = 7 for the 20-min time point, P = 0.16
Kruskal-Wallis ANOVA). (D) A 1-h pretreatment with 1 μM FTY720 blocks the ability of 100 nM SEW2871 and subsequent 1 μM S1P to sensitize
sensory neurons (n = 6, P = 0.39 Friedman RM ANOVA on ranks). AP - action potential, Cont - control, S1P - sphingosine-1-phosphate.
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FTY720 for 1 h. As shown in Figure 8D, under control
conditions, the ramp evoked an average of 2.8 ± 0.3 APs
(n = 6). To specifically test whether the sensitization was
mediated by activation of S1PR1, these sensory neurons
were exposed to 100 nM SEW2871, a selective S1PR1
agonist. After prolonged treatment with FTY720, SEW2871
failed to augment AP firing (3.3 ± 0.6 APs after a 10-min
exposure, n = 6). These same neurons were then exposed to
the more global agonist, S1P (1 μM), which also did not en-
hance AP firing (3.2 ± 0.7 APs after a 10-min exposure).
There was no significant difference between the control
values and any of the treatment time points (P = 0.39,
RM ANOVA on ranks). Similarly, after pretreatment with
FTY720, neither SEW2871 nor S1P had any effect on
the resting membrane potential (control −61.8 ± 4.9 mV,
10-min SEW2871 − 63.2 ± 6.4 mV, 10-min S1P −60.6 ±
6.6 mV, n = 6, P = 0.96 RM ANOVA). In contrast, two un-
treated sensory neurons isolated from the same tissue har-
vests were sensitized after exposures to SEW2871 and S1P(control both cells evoked 3 APs, 10-min SEW2871 13 and
8 APs, and 10-min S1P 8 and 10 APs, respectively, data not
shown). A 1-h pretreatment with 30 nM FTY720 did not
block the capacity of 1 μM S1P to sensitize sensory neu-
rons; in these two neurons, 3 APs were evoked under con-
trol conditions whereas, after a 10-min exposure to 1 μM
S1P, the ramp evoked 14 and 9 APs. In a separate series
of experiments, a 1-h pretreatment with 1 μM FTY720
blocked the capacity of 1 μM S1P to sensitize sensory neu-
rons (data not shown; control 3.6 ± 0.3 APs vs. S1P at
10 min 5.0 ± 0.7 APs, n = 7); however, this FTY720 pretreat-
ment had no effect on the subsequent enhancement of ex-
citability produced by the exposure to 1 μM PGE2 (after
2 min 7.4 ± 0.7 APs and after 10 min 8.2 ± 0.7 APs, P < 0.05
vs. the control or the 10-min S1P, ANOVA on ranks).
Therefore, these results demonstrate that FTY720-P acutely
functions as an agonist to increase neuronal excitability and
that prolonged treatment with this agonist leads to suppres-
sion of sensitization produced by either SEW2871 or S1P.
A corollary to this result is that because FTY720-P does
Figure 9 (See legend on next page.)
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Figure 9 Acute CYM-5442 exposure increases neuronal excitability, but prolonged treatment blocks sensitization to SEW2871, but not to S1P. (A)
summarizes the acute effects of 100 nM CYM-5442 on sensory neurons. In one group, CYM-5442 significantly increased the number of APs after
only a 4-min exposure (n = 4), whereas the other group appeared to be insensitive to CYM-5442 (n = 4). (B) demonstrates that after a 1-h
pretreatment with 100 nM CYM-5442, the S1PR1 selective agonist SEW2871 (100 nM) fails to increase the neuronal excitability (n= 10 control-10 min,
n= 8 15 min). (C) shows that in a total of 15 sensory neurons, 10 were insensitive to 1 μM S1P although there was a small but significant increase in the
number of APs measured only at the 10-min point. In contrast, five sensory neurons exhibited increased excitability in response to S1P. (D) demonstrates
that after normalization of the number of APs to their respective control values, there was no difference in the average number of APs after exposure
to 100 nM SEW2871 or in those neurons that appeared to be insensitive to 1 μM S1P. However, there was a significant increase in the number
of APs in those sensory neurons that were sensitive to 1 μM S1P. For the 6-min point, the increase measured in the S1P-sensitive neurons was
significant compared to all the SEW2871 time points, all the S1P-insensitive times except for the 10-min point, and the S1P-sensitive control. For
the 10- and 15-min points, the increase measured in the S1P-sensitive neurons was significant compared to all the SEW2871 and S1P-insensitive
time points, as well as the S1P-sensitive control and the 2-min point (P < 0.001 ANOVA Holm-Sidak all-pairs test). AP - action potential, Cont - control,
S1P - sphingosine-1-phosphate.
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ability after FTY720 treatment, this would clearly indi-
cate that activation of S1PR2 is not sufficient to sensitize
sensory neurons.
Pretreatment with the S1PR1 agonist, CYM-5442, prevents
SEW2871, but not S1P, from increasing excitability;
CYM-5442 also serves as a functional antagonist
CYM-5442 is a selective agonist for S1PR1, and treat-
ment with this compound, like FTY720, leads to the in-
ternalization and ubiquitination S1PR1 [60,61]. Using a
similar approach as described above for FTY720, acute
treatment with 100 nM CYM-5442 produced a signifi-
cant increase in the excitability of small-diameter sen-
sory neurons (see Figure 9A). As with FTY720, in a total
of eight neurons, four neurons were sensitized by CYM-
5442 within a 4-min exposure; however, four neurons
remained insensitive to CYM-5442 even after 15 min.
To test the idea that a prolonged treatment with CYM-
5442 could lead to the down-regulation of S1PR1, we
found that after a 1-h pretreatment with 100 nM CYM-
5442, exposure to the selective agonist for S1PR1,
SEW2871 (100 nM), failed to augment the excitability
(Figure 9B). For example, after a 10-min application of
SEW2871, the average number of APs (3.5 ± 0.5, n = 10)
was not different than that obtained under control
conditions (3.1 ± 0.1, n = 10, P = 0.44, Kruskal-Wallis
ANOVA). These results suggest that CYM-5442 led to
the selective down-regulation of S1PR1. If that is the
case, then after prolonged treatment with CYM-5442,
exposure to S1P should reveal the contributions of other
S1PRs, namely S1PR3, to the S1P-mediated sensitization.
As shown in Figure 9C, in a total of 15 neurons, expos-
ure to 1 μM S1P did not alter the number of evoked
APs in 10 neurons, although there was a small but sig-
nificant increase in the average number of evoked APs
measured at 10 min (control 3.7 ± 0.2 APs vs. 10 min
5.3 ± 0.21 APs, P = 0.002 Kruskal-Wallis ANOVA). How-
ever, in five neurons, the number of APs was signifi-
cantly increased to 9.4 ± 1.2 from a control value of3.4 ± 0.3 APs (P < 0.001, RM ANOVA Holm-Sidak all-
pairs test). To reduce the variability in those sensory
neurons pretreated with CYM-5442 and then exposed to
these different agonists, the number of APs obtained for
the different treatments was normalized to their respect-
ive values obtained for the control condition. As sum-
marized in Figure 9D, there was no difference in the
normalized number of APs obtained after exposure to
SEW2871 compared to those neurons that were insensi-
tive to S1P whereas there was a significant increase in the
number of evoked APs in those sensory neurons that were
sensitive to S1P. Thus, these results indicate that approxi-
mately one third of these CYM-5442-treated sensory neu-
rons exhibited an increased excitability after exposure to
S1P and, based on the results described above, suggest
that S1PR3 likely mediates this effect. In addition, these
results are similar to our previous findings wherein treat-
ment with siRNA targeted to S1PR1 blocked the sensitization
produced by SEW2871, yet in one third of these neu-
rons (three of nine total), S1P produced a significant,
twofold increase in the excitability [15].
S1P does not activate a membrane current in sensory
neurons
A previous study [62] indicated that S1P, via S1PR3, was
capable of directly mediating a membrane current con-
ducted by chloride and is believed to result in the direct
activation of nociceptive sensory neurons. As our work
described above indicates that both S1PR1 and R3 medi-
ate the sensitization of sensory neurons, the potential
role of a S1PR3-induced current in regulating the excit-
ability of sensory neurons was examined. As shown in a
representative current-clamp recording obtained from a
small-diameter (<25 μm) sensory neuron isolated from
the rat DRG, a ramp of depolarizing current evoked 3
APs (left panel Figure 10A). However, in a voltage-clamp
recording from this same neuron (holding potential
of −60 mV, see the ‘Methods’ section for details), a 60-s
exposure to 1 μM S1P via bath superfusion failed to pro-
duce a measureable change in membrane current (right
Figure 10 S1P does not evoke a change in membrane current in
small-diameter sensory neurons. (A) Left panel shows a representative
current-clamp recording where the ramp of depolarizing current evoked
3 APs in a small-diameter capsaicin-sensitive rat sensory neuron. The
right panel shows the membrane current (holding voltage −60 mV)
in response to a 60-s bath application of 1 μM S1P; the trace shows
points at 20-ms intervals in order to reduce the dataset size; the inset
represents an expanded portion of the current (35 to 235 s). (B) Left
panel demonstrates a representative current-clamp recording where
the ramp of depolarizing current evoked 2 APs in a small-diameter
capsaicin-sensitive mouse sensory neuron. The right panel shows the
membrane current (holding voltage −60 mV, 20-ms interval) in response
to a 60-s bath application of 1 μM S1P. (C) Left panel shows that the
ramp evokes 4 APs in this small-diameter capsaicin-sensitive mouse
sensory neuron. The right panel shows the membrane current (holding
voltage −60 mV, 20-ms interval) in response to a 60-s bath application
of 100 μM S1P. In the left panels, the dotted line represents the 0 mV
level; in the right panels, the line noted with 0 marks the zero-current
level. (D) Medium- to large-diameter sensory neurons are not sensitized
by S1P. Exposure of medium- to large-diameter sensory neurons
isolated from rat DRG to 1 μM S1P by either bath superfusion
(n = 7) or micro-injection of a stock into the bath (n = 8) does
not alter the excitability. AP - action potential, Cont - control,
S1P - sphingosine-1-phosphate.
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sensitive sensory neurons (23.9 ± 0.6 μm), 1 μM S1P did
not evoke any change in the existing membrane current.
The studies performed by Camprubi-Robles et al. [62]
used sensory neurons isolated from the mouse DRG.
However, in small-diameter capsaicin-sensitive sensory
neurons isolated from the mouse DRG, we found that
1 μM S1P did not evoke a change in membrane current
(representative recording shown in Figure 10B, n = 7,
average diameter 23.6 ± 0.7 μm). Furthermore, both 10
and 100 μM S1P failed to evoke any change in mem-
brane current. In five mouse sensory neurons (average
diameter 23.8 ± 0.4 μm, two capsaicin-sensitive, two
capsaicin-insensitive, one lost before capsaicin applica-
tion), 10 μM S1P was ineffective. In another three mouse
sensory neurons (see representative recording in Figure 10C,
average diameter 21.0 ± 1.0 μm, all three capsaicin-sensitive),
100 μM S1P evoked no change in the current. These re-
sults demonstrate that S1P, even at a high concentration,
failed to elicit a change in membrane current in either rat
or mouse small-diameter sensory neurons under our nor-
mal recording conditions. Although S1P can enhance the
excitability of small-diameter sensory neurons, it appears
to do so without evoking a direct change in membrane
current. Based on this, the ability of S1P to enhance the
excitability of medium- to large-diameter (>40 μm) sen-
sory neurons isolated from rat DRG was determined. In
these larger sensory neurons (average diameter 41.6 ±
0.4 μm), a 20-min exposure to 1 μM S1P did not increase
the number of APs evoked by a ramp of depolarizing
current (see Figure 10D, control 2.7 ± 0.2 APs, n = 15 vs.
20-min S1P 2.9 ± 0.6 APs, n = 13, P = 0.85 ANOVA on
ranks). In addition, exposure to S1P did not alter the rest-
ing membrane potential in these neurons (data not shown,
control −57.0 ± 0.9 mV vs. S1P 20 min −57.5 ± 1.6 mV,
P = 0.87 ANOVA). S1P was applied by two different ap-
proaches, bath superfusion (n = 7) and micro-pipetting
into the bath from a 100 μM stock solution (n = 8); neither
of these delivery methods increased the number of evoked
APs; the results obtained with these two methods were
not statistically different, so they have been combined in
Figure 10D. Taken together, these results suggest that
small-, but not medium-large, diameter sensory neurons
can be sensitized by S1P and that S1P cannot directly alter
the membrane current in small-diameter sensory neurons
isolated from either the rat or mouse DRG.
Discussion
In this report, we demonstrate that S1P enhances the ex-
citability of sensory neurons through the activation of
S1PR1 and/or R3. A variety of approaches were used to
isolate the contributions of specific receptors to the neur-
onal sensitization mediated by S1P. siRNAs targeted to in-
dividual S1PRs demonstrated that specific knockdown of
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vent the sensitization produced by S1P. The results ob-
tained with the specific agonist of S1PR3, CYM-5541, as
well as pharmacological antagonists (W146, CAY10444,
and the VPC compounds) are consistent with the idea that
activation of S1PR1 and/or R3 augment excitability. Lastly,
both FTY720 and CYM-5442 acutely increased the excit-
ability of these sensory neurons. However, prolonged
treatment with FTY720, which targets S1PR1, R3, R4, and
R5, blocked the sensitization produced by either SEW2871
or S1P. In contrast, CYM-5442, which is selective for
S1PR1, suppressed the effects of SEW2871 in all neurons,
whereas the sensitizing actions of S1P still remained in
approximately one third of the CYM-5442-treated sensory
neurons. Therefore, these findings establish that the
enhanced excitability produced by S1P results from the
activation of S1PR1 and/or R3 but that R2, R4, and R5
are insufficient.
Our previous work indicated that S1PR1 played a prom-
inent, although not exclusive, role in enhancing the excit-
ability of small-diameter sensory neurons where treatment
with siRNA targeted to S1PR1 completely blocked the
SEW2871-induced sensitization, but in about one third of
these siRNA treated-neurons, exposure to S1P was cap-
able of producing significant increases in AP firing [15]. In
a real-time single-cell qPCR study of the mRNA levels of
the different S1PRs in isolated sensory neurons, we found
that in small- (<25 μm, n = 18), medium- (25 to 40 μm,
n = 17), and large-diameter (>50 μm, n = 17) neurons,
S1PR1 was the highest expressing subtype in more than
half (>10) of the total individual cells in each group [14].
In those neurons with S1PR1 as the highest expressor, five
of the ten small- and five of the ten medium-diameter
neurons expressed S1PR3 as the second highest subtype.
In addition, there was a strong correlation between the
expression of S1PR1 and R3 in both small- and medium-
diameter sensory neurons (Pearson’s correlation coeffi-
cients of 0.89 and 0.92, respectively) [14]. Thus, after
S1PR1, S1PR3 was the second highest expressor in ap-
proximately 50% of these identified neurons. These results
are consistent with our previous siRNA studies examining
the functional response of S1PR1 as well as those de-
scribed above where the down-regulation of S1PR1 by
CYM-5442 yields a group of neurons that were responsive
to S1P, but not SEW2871. Based on the capacities of
FTY720 and CYM-5442 to act as functional antagonists,
these results suggest that after CYM-5442-induced down-
regulation of S1PR1, S1PR3 remains capable of activation.
The potential differences in cellular responses mediated
by S1PR1 compared to S1PR3 may result from coupling to
different G proteins and their respective downstream ef-
fectors. S1PR1 is believed to couple with only Gi/o whereas
S1PR3 can couple with Gi/o, Gq/11, or G12/13, thus leading
to the activation of a variety of effector systems; seereviews [5,63-65]. However, the specific roles of S1PR1
and R3 in the regulation of neuronal excitability remain to
be defined and will be the focus of future investigations.
In addition, other studies support a role for S1P-S1PR1
in regulating the sensitivity of nociceptive sensory neurons.
Opioid-induced hyperalgesia significantly decreased the la-
tency of paw withdrawal to a thermal stimulus; this en-
hanced sensitivity was associated with a fourfold increase
in the levels of S1P measured in the dorsal horn of the
spinal cord [66]. Both the heightened sensitivity and the
increase in S1P were blocked by pretreatment with either
N-N-dimethylsphingosine or SK-I, inhibitors of sphingo-
sine kinases. Injection of either S1P or SEW2871 into the
rat or mouse paw produced thermal hyperalgesia ([13,10],
respectively), which was blocked by treatment with W146,
a selective antagonist for S1PR1 [13]. Localized perfusion
of the L5 DRG with S1P increased the sensitivity of the
rat’s paw to mechanical stimulation (by von Frey hairs)
[67]. These authors also showed that localized injection of
the inflammatory agent, zymosan, at the L5 DRG resulted
in mechanical hypersensitivity of the hindpaw. However, a
prior localized injection of siRNA targeted to S1PR1 at the
L4/L5 DRG significantly reduced this hypersensitivity, sug-
gesting that S1PR1 played a key role in the onset of this
inflammatory-induced hypersensitivity [67].
An earlier study demonstrated that both intraperitonal
and intrathecal delivery of FTY720 could reduce the
nociceptive behaviors associated with either the inflam-
matory formalin model (number of flinches) or the
neuropathic spared-nerve injury model (mechanical
thresholds) [68]. Interestingly, effective doses of FTY720
did not have significant effects on the numbers of circu-
lating white blood cells or lymphocytes, suggesting that
the anti-nociceptive effects were not mediated by the
immunosuppressive actions of FTY720. In contrast, the
selective S1PR1 agonist, SEW2871, had no analgesic ef-
fect on the formalin-induced hypersensitivity.
Recently, it was shown that the intrathecal injection of
SEW2871 produced a hypersensitivity (both allodynia and
hyperalgesia) to mechanical stimulation of the rat’s hind-
paw; this hypersensitivity was blocked by the S1PR1 select-
ive antagonist, W146 [69]. Interestingly, the mechanical
hypersensitivity resulting from the repeated injection of
the chemotherapeutic agent, paclitaxel, was also blocked
by W146 in a dose-dependent manner, suggesting that
S1P-S1PR1 may play a role in the chemotherapy-induced
peripheral neuropathy caused by paclitaxel. The peak of
the increased sensitivity resulting from paclitaxel was
associated with increased activity in the enzymes regulat-
ing the ceramide-sphingosine-S1P pathway, notably
sphingosine kinase. Consistent with the idea that the
paclitaxel-induced hypersensitivity was associated with
S1P-S1PR1, prior intrathecal treatment with either
FTY720 or CYM-5442 blocked, in a dose-dependent
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or paclitaxel. Of significance, established paclitaxel-induced
hypersensitivity could be reversed by exposure to either
W146, FTY720, or CYM-5442, but not SEW2871. No ef-
fect on circulating white blood cells was observed. These
results in combination with those results obtained by
Coste et al. [68] strongly support the idea that antagonism
rather than activation of S1PR1 is a key target in the sup-
pression of this neuronal hypersensitivity. In future stud-
ies, it will be important to establish the signaling cascades
that are activated by S1P-S1PR1 and determine the specific
effectors that mediate the increased sensitivity as possible
therapeutic targets.
A number of studies have established that the S1P-
S1PR1 pathway plays a significant role in regulating the
sensitivity of nociceptive sensory neurons through both
cellular and behavioral approaches. However, in addition
to our results described above, only one other study has
explored the possible role of S1PR3 in regulating the
sensitivity of sensory neurons. Camprubi-Robles et al.
[62] demonstrated that S1P, presumably through activa-
tion of S1PR3, was capable of directly mediating a mem-
brane current in nearly all sensory neurons isolated from
the mouse DRG. Although neither the recordings of the
reversal potential nor the concentration dependence
were shown, application of 100 μM niflumic acid has-
tened the recovery phase of the S1P-induced current,
suggesting that it was conducted by chloride. In current-
clamp recordings, these authors report that 1 μM S1P,
on average, depolarized the resting membrane potential
from −54 to −36 mV with an increase in spontaneous
AP firing. Our results demonstrate that FTY720 also
depolarized the resting membrane potential by a similar
amount (−54 to −39 mV); however, there was no enhance-
ment of spontaneous activity, only AP firing evoked by the
current ramp. We did observe a large depolarization in re-
sponse to high concentrations of either CYM-5541 or
SEW2871, and based on the suppressive effects of W146,
this depolarization is thought to result from activation of
S1PR1. In S1PR3−/− knockout mice, Camprubi-Robles et
al. found that S1P depolarized the neuron by only approxi-
mately 5 mV; however, no membrane current recordings
from the S1PR3−/− mice were shown. Using a fura-2-based
assay, Camprubi-Robles et al. indicate that, in normal wild-
type mice, approximately 60% of the neurons were respon-
sive to 1 μM S1P and that niflumic acid reduced this to
approximately 14%. However, in the S1PR3−/− mice, 40%
of the neurons responded to S1P; if S1PR3 specifically me-
diates this response, it is curious why the knockout is not
more similar to the actions of niflumic acid. Although the
authors claim that this S1P-mediated current was exhibited
by nearly all neurons, our experiments in both rat and
mouse small-diameter sensory neurons failed to detect any
measurable change in membrane current after exposure toeven high concentrations of S1P (10 and 100 μM). In
addition, S1P failed to augment the excitability in medium-
to large-diameter rat sensory neurons. The basis for this
difference remains an open question. One possibility could
be differences in the culture media. In the Camprubi-
Robles et al. study, sensory neurons were maintained in a
synthetic serum-free medium supplemented with high
levels of NGF (100 ng/ml) whereas, in our experiments,
sensory neurons were maintained in an F-12 medium sup-
plemented with 10% heat-inactivated horse serum and a
lower concentration of NGF (30 ng/ml).
Conclusions
Our results demonstrate that although S1PR1 plays a
prominent role in enhancing the excitability of small-
diameter sensory neurons, activation of S1PR3 can lead to
the augmentation of current-evoked AP firing. Clearly,
additional studies will be required to fully elucidate the
mechanistic role of S1PR3 in regulating neuronal excitabil-
ity and sensitivity to nociceptive stimulation. Important
future work could establish whether there are significant
functional interactions between S1PR1 and R3 or potential
interplay between their downstream signaling pathways
that mediate the sensitization of sensory neurons.
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